In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs

Molecules

Volumn 13, Issue 9, 2008, Pages 2136-2155

  Onishi, Hiraku ^a   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Controlled release; In vivo behavior; Macromolecular prodrug; Microparticles; Nanoparticles

Indexed keywords

DEXTRAN; MITOMYCIN; NANOPARTICLE; PRODRUG;

ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TRACT; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; DELAYED-ACTION PREPARATIONS; DEXTRANS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; MITOMYCIN; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NANOPARTICLES; PRODRUGS;

EID: 53249151922     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules13092136     Document Type: Review

References (84)

1. Cavallaro, G.; Pitarresi, G.; Licciardi, M.; Giammona, G. Polymeric prodrug for release of an antitumoral agent by specific enzymes. Bioconjug Chem. 2001, 12, 143-151.
2. Kratz, F.; Abu Ajaj K.; Warnecke, A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Investig. Drugs 2007, 16, 1037-1058.
3. Julyan, P.J.; Seymour, L.W.; Ferry, D.R.; Daryani, S.; Boivin, C.M.; Doran, J.; David, M.; Anderson, D.; Christodoulou, C.; Young, A.M.; Hesslewood, S.; Kerr, D.J. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Control. Release 1999, 57, 281-290.
4. Ulbrich, K.; Etrych, T.; Chytil, P.; Jelínková, M.; Ríhová, B. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J. Control. Release 2003, 87, 33-47.
5. Singer, J.W.; Bhatt, R.; Tulinsky, J.; Buhler, K.R.; Heasley, E.; Klein, P.; de Vries, P. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J. Control. Release 2001, 74, 243-247.
6. Zou, Y.; Fu, H.; Ghosh, S.; Farquhar, D.; Klostergaard, J. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 2004, 10, 7382-7391.
7. Takakura, Y.; Matsumoto, S.; Hashida, M.; Sezaki, H. Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res. 1984, 44, 2505-2510.
8. Okuno, S.; Harada, M.; Yano, T.; Yano, S.; Kiuchi, S.; Tsuda, N.; Sakamura, Y.; Imai, J.; Kawaguchi, T.; Tsujihara, K. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000, 60, 2988-2995.
9. Trouet, A.; Masquelier, M.; Baurain, R.; Deprez-De Campeneere D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U S A. 1982, 79, 626-629.
10. Kaneo, Y.; Tanaka, T.; Iguchi S. Preparation and properties of a mitomycin C-albumin conjugate. Chem. Pharm. Bull. 1990, 38, 2614-2616.
11. Takakura, Y.; Takagi, A.; Hashida, M.; Sezaki, H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 1987, 4, 293-300.
12. Yamaoka, T.; Kuroda, M.; Tabata, Y.; Ikada, Y. Body distribution of dextran derivatives with electric charges after intravenous administration. Int. J. Pharm. 1995, 113, 149-157.
13. Takakura, Y.; Fujita, T.; Hashida, M.; Sezaki, H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 1990, 7, 339-346.
14. Matsumura, Y.; Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387-6392.
15. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284.
16. Unezaki, S.; Maruyama, K.; Ishida, O.; Suginaka, A.; Hosoda, J.; Iwatsuru, M. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol). Int. J. Pharm. 1995, 126, 41-48.
17. Nakanishi, T.; Fukushima, S.; Okamoto, K.; Suzuki M.; Matsumura, Y.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 2001, 74, 295-302.
18. Kato, A.; Takakura, Y.; Hashida, M.; Kimura, T.; Sezaki H. Physico-chemical and antitumor characteristics of high molecular weight prodrugs of mitomycin C. Chem. Pharm. Bull. 1982, 30, 2951-2957.
19. Duncan, R.; Hume, I.C.; Kopecková, P.; Ulbrich, K.; Strohalm, J.; Kopecek, J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of daunomycin conjugates against mouse leukaemia L1210 in vivo. J. Control. Release 1989, 10, 51-63.
20. 4-(4-carboxybutyryl)-1-beta-D-arabinofuranosylcytosine and its conjugate with poly-L-lysine or decylenediamine-dextran T70. Chem. Pharm. Bull. 1989, 37, 1587-1590.
21. Kovár, M.; Kovár, L.; Subr, V.; Etrych, T.; Ulbrich, K.; Mrkvan, T.; Loucká, J.; Ríhová, B. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro. J. Control. Release 2004, 99, 301-314.
22. Oyama, T.; Kawamura, M.; Abiko, T.; Izumi, Y.; Watanabe, M.; Kumazawa, E.; Kuga, H.; Shiose, Y.; Kobayashi, K. Hyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer. Oncol. Rep. 2007, 17, 653-659.
23. Conover, C.D.; Greenwald, R.B.; Pendri, A.; Gilbert, C.W.; Shum, K.L. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 1998, 42, 407-414.
24. Caiolfa, V.R.; Zamai, M.; Fiorino, A.; Frigerio, E.; Pellizzoni, C.; d'Argy, R.; Ghiglieri, A.; Castelli, M.G.; Farao, M.; Pesenti, E.; Gigli, M.; Angelucci, F.; Suarato, A. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Control. Release 2000, 65, 105-119.
25. Harada, M.; Sakakibara, H.; Yano, T.; Suzuki, T.; Okuno, S. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J. Control. Release 2000, 69, 399-412.
26. Sugahara, S.; Kajiki, M.; Kuriyama, H.; Kobayashi, T.R. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J. Control. Release 2007, 117, 40-50.
27. Kratz, F.; Abu Ajaj, K.; Warnecke, A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Investig. Drugs. 2007, 16, 1037-1058.
28. Endo. N.; Kato, Y.; Takeda, Y.; Saito, M.; Umemoto, N.; Kishida, K.; Hara, T. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody. Cancer Res. 1987, 47, 1076-1080.
29. Burger, A.M.; Hartung, G.; Stehle, G.; Sinn, H.; Fiebig, H.H. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int. J. Cancer 2001, 92, 718-724.
30. Kato, Y.; Saito, M.; Fukushima, H.; Takeda, Y.; Hara, T. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Cancer Res. 1984, 44, 25-30.
31. 4-(4-carboxybutyryl)-ara-C with ethylenediamine- introduced dextran and its resistance to cytidine deaminase. Drug Des. Deliv. 1990, 6, 273-280.
32. Tanaka, T.; Kaneo, Y.; Iguchi, S. Properties of mitomycin C-albumin conjugates in vitro and in vivo. Bioconjug. Chem. 1991, 2, 261-269.
33. Kato, Y.; Onishi, H.; Machida, Y. Efficacy of lactosaminated and intact N-succinylchitosan-mitomycin C conjugates against M5076 liver metastatic cancer. J. Pharm. Pharmacol. 2002, 54, 529-537.
34. Sugibayashi, K.; Morimoto, Y.; Nadai, T.; Kato, Y.; Hasegawa, A.; Arita, T. Drug-carrier property of albumin microspheres in chemotherapy. II. Preparation and tissue distribution in mice of microsphere-entrapped 5-fluorouracil. Chem. Pharm. Bull. 1979, 27, 204-209.
35. 141Ce-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs. J. Pharm. Sci. 1980, 69, 755-762.
36. Bazile, D.; Prud'homme, C.; Bassoullet, M.T.; Marlard, M.; Spenlehauer, G.; Veillard, M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995, 84, 493-498.
37. Desai, M.P.; Labhasetwar, V.; Amidon, G.L.; Levy, R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13, 1838-1845.
38. Dunn, S.E.; Coombes, A.G.A.; Garnett, M.C.; Davis, S.S.; Davies, M.C.; Illum, L. In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J. Control. Release 1997, 44, 65-76.
39. Tabata, Y.; Murakami, Y.; Ikada, Y. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J. Control. Release 1998, 50, 123-133.
40. Mosqueira, V.C.; Legrand, P.; Gref, R.; Heurtault, B.; Appel, M.; Barratt, G. Interactions between a macrophage cell line (J774A1) and surface-modified poly (D,L-lactide) nanocapsules bearing poly(ethylene glycol). J. Drug Target. 1999, 7, 65-78.
41. Zambaux, M.F.; Bonneaux, F.; Gref, R.; Dellacherie, E.; Vigneron, C. MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. J. Biomed. Mater. Res. 1999, 44, 109-115.
42. Nguyen, C.A. Allemann, E.; Schwach, G.; Doelker, E.; Gurny, R. Cell interaction studies of PLA-MePEG nanoparticles. Int. J. Pharm. 2003, 254, 69-72.
43. Yoshioka, M.; Hashida , M.; Muranihsi, S.; Sezaki, H. Specific delivery of mitomycin C to the liver, spleen and lung: nano- and microspherical carriers of gelatin. Int. J. Pharm. 1981, 81, 131-141.
44. Leopold, C.S.; Friend, D.R. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J. Pharmacokinet. Biopharm. 1995, 23, 397-406.
45. Mehvar, R.; Dann, R.O.; Hoganson, D.A. Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes. J. Control. Release 2000, 68, 53-61.
46. Rensberger, K.L.; Hoganson, D.A.; Mehvar, R. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: in vitro immunosuppressive effects on rat blood and spleen lymphocytes. Int. J .Pharm. 2000, 207, 71-76.
47. Zhang, X.; Mehvar, R. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: plasma and tissue disposition. J. Pharm. Sci. 2001, 90, 2078-2087.
48. Yano, H.; Hirayama, F.; Kamada, M.; Arima, H,; Uekama, K. Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J. Control. Release 2002, 79, 103-112.
49. Tozaki, H.; Fujita, T.; Komoike, J.; Kim, S.I.; Terashima, H.; Muranishi, S.; Okabe, S.; Yamamoto, A. Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J. Pharm. Pharmacol. 1999, 51, 257-261.
50. Nakase, H.; Okazaki, K.; Tabata, Y.; Uose, S.; Ohana, M.; Uchida, K.; Matsushima, Y.; Kawanami, C.; Oshima, C.; Ikada, Y.; Chiba, T. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther. 2000, 292, 15-21.
51. Lamprecht, A.; Ubrich, N.; Yamamoto, H.; Schäfer, U.; Takeuchi, H.; Maincent, P.; Kawashima, Y.; Lehr, C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 2001, 299, 775-781.
52. Tozaki, H.; Odoriba, T.; Okada, N.; Fujita, T.; Terabe, A.; Suzuki, T.; Okabe, S.; Muranishi, S.; Yamamoto, A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J. Control. Release 2002, 82, 51-61.
53. Onishi, H.; Oosegi, T.; Machida, Y.; McGinity, J.W. Preparation and in vitro evaluation of chitosan microspheres containing prednisolone: comparison of simple and conjugate microspheres. Drug Dev. Ind. Pharm. 2005, 31, 597-605.
54. Onishi, H.; Oosegi, T.; Machida, Y. Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis, Int. J. Pharm. 2008, 358, 271-277.
55. Oosegi, T.; Onishi, H.; Machida, Y. Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int. J. Pharm. 2008, 348, 80-88.
56. Sato, M.; Onishi, H.; Takahara, J.; Machida, Y.; Nagai, T. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Biol. Pharm. Bull. 1996, 19, 1170-1177.
57. Sato, M.; Onishi, H.; Kitano, M.; Machida, Y.; Nagai T. Preparation and drug release characteristics of the conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Biol. Pharm. Bull. 1996, 19, 241-245.
58. Song, Y.; Onishi, H.; Nagai, T. Synthesis and drug-release characteristics of the conjugates of mitomycin C with N-succinyl-chitosan and carboxymethyl-chitin. Chem. Pharm. Bull. 1992, 40, 2822-2825.
59. Song, Y.; Onishi, H.; Nagai, T. Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate. Biol. Pharm. Bull. 1993, 16, 48-54.
60. Song, Y.; Onishi, H; Machida, Y.; Nagai, T. Particle characteristics of carboxymethyl-chitin-mitomycin C conjugate and N-succinyl-chitosan-mitomycin C conjugate and their distribution and histological effect in some tissues, S. T. P. Pharma Sci. 1995, 5, 162-170.
61. Onishi, H.; Takahashi, H.; Yoshiyasu, M.; Machida, Y. Preparation and in vitro properties of N-succinylchitosan-or carboxymethylchitin-mitomycin C conjugate microparticles with specified size. Drug Dev. Ind. Pharm. 2001, 27, 659-667.
62. Onishi, H.; Kume, K.; Koyama, K.; Machida, Y. Preparation of carboxymethylchitin nanoparticles by covalent crosslinking and their in vitro evaluation, Open Drug Deliv. J. 2008, 2, 20-25.
63. Okada, H.; Heya, T.; Ogawa, Y.; Shimamoto, T. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther. 1988, 244, 744-750.
64. Ogawa, Y.; Okada, H.; Yamamoto, M.; Shimamoto, T. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers. Chem. Pharm. Bull. 1988, 36, 2576-2781.
65. Machida, Y.; Onishi, H.; Kurita, A.; Hata, H.; Morikawa, A.; Machida, Y. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J. Control. Release 2000, 66, 159-175.
66. Takahashi, H.; Onishi, H.; Machida, Y. Glycyrrhetic acid-loaded microparticles: liver-specific delivery and therapeutic potential against carbon tetrachloride-induced hepatitis. J. Pharm. Pharmacol. 2004, 56, 437-444.
67. Oh, J.E; Nam, Y.S.; Lee, K.H.; Park, T.G. Conjugation of drug to poly(D,L-lactic-co-glycolic acid) for controlled release from biodegradable microspheres. J. Control. Release 1999, 57, 269-280.
68. Park, T.G. Degradation of poly(-lactic acid) microspheres: effect of molecular weight. J. Control. Release 1994, 30, 161-173.
69. Yoo, H.S.; Oh, J.E.; Lee, K.H.; Park, T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 1999, 16, 1114-1118.
70. Yoo, H.S.; Lee, K.H.; Oh, J.E.; Park, T.G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Control. Release 2000, 68, 419-431.
71. Fiocchi, C. Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol. Dietol. 2002, 48, 215-226.
72. Campieri, M.; Ferguson, A.; Doe, W.; Persson, T.; Nilsson, L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997, 41, 209-214.
73. Rutgeerts, P. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. Mediators Inflamm. 1998, 7, 137-140.
74. Friend, D.R. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. 2005, 57, 247-265.
75. Lamprecht, A.; Schafer, U.; Lehr, C.M. Microparticle targeting to the inflamed colonic mucosa for the treatment of inflammatory bowel disease: in vivo results from rat. AAPS PharmSci. 2000, 2(S1), 1930.
76. Lamprecht, A.; Schafer, U.; Lehr, C.M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 2001, 18, 788-793.
77. Tabata, Y.; Ikada, Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 1988, 9, 356-362.
78. Tabata, Y.; Inoue, Y.; Ikada, Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 1996, 14, 1677-1685.
79. Oosegi, T.; Onishi, H.; Machida, Y. Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur. J. Pharm. Biopharm. 2008, 68, 260-266.
80. Silva, M.; Lara, A.S.; Leite, C.Q.; Ferreira, E.I. Potential tuberculostatic agents: micelle-forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with isoniazid. Arch. Pharm. (Weinheim) 2001, 334, 189-193.
81. Hans, M.; Shimoni, K.; Danino, D.; Siegel, S.J.; Lowman, A. Synthesis and characterization of mPEG-PLA prodrug micelles. Biomacromolecules 2005, 6, 2708-2717.
82. Silva, M.; Ricelli, N.L.; El Seoud O.; Valentim, C.S.; Ferreira, A.G.; Sato, D.N.; Leite, C.Q.F.; Ferreira, E.I. Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug. Arch. Pharm. (Weinheim) 2006, 339, 283-290.
83. Silva, M.; Ferreira, E.I.; Leite, C.Q.F.; Sato, D.N. Preparation of polymeric micelles for use as carriers of tuberculostatic drugs. Trop. J. Pharm. Res. 2007, 6, 815-824.
84. Li, X.;, Wu, Q.;, Lu, M.; Zhang, F.; Lin, X. Novel hepatoma-targeting micelles based on chemoenzymatic synthesis and self-assembly of galactose-functionalized ribavirin-containing amphophilic random copolymer. J. Polym. Sci. Part A: Polym .Chem. 2008, 46, 2734-2744.